756 A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC)
Jonathan W. Riess(University of California Davis Medical Center), Pilar Garrido(Hospital Universitario Ramón y Cajal), Marcos Iglesias, Tanguy Y. Seiwert(Georgetown University), Ayako Wakatsuki Pedersen(Newcastle upon Tyne Hospitals NHS Foundation Trust), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), James Spicer(King's College London), Amy Wesa, P. Nicholas Shaw(Velindre Cancer Centre), Laura Medina(Instituto de Investigación Biomédica de Málaga), Jaime Rubio(Hospital Universitario Fundación Jiménez Díaz), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Cecilie Abildgaard(Danish Cancer Society), Qasim Ahmad, Diane Opatt McDowell(GlaxoSmithKline (United States))
Cited by 1
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k